Public Health or Corporate Wealth?
I am sitting in an auditorium at Georgetown University attending a symposium on the influence of the pharmaceutical industry on scientific publications and continuing medical education. This is a decidedly hostile crowd. The crusaders are all here, including Arnold Relman, MD, professor of medicine at Harvard Medical School. He is a former editor of the New England Journal of Medicine (1977–91) and evidences such vigorous idealism I cannot believe he was born in 1923.